Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
SAN DIEGO--(BUSINESS WIRE)-- Endeavor BioMedicines ('Endeavor'), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that two posters have been accepted for presentation at the American Thoracic Society 2025 (ATS 2025) International Conference. ATS 2025 will take place May 16-21, 2025, in San Francisco.
Following are details about the Endeavor poster presentations at ATS 2025:
Title: Deep Learning-based Disease Severity Biomarkers on CT; Posthoc Analysis in a Phase 2a Placebo-controlled Study of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis
Abstract Session: C23 – On The Horizon: Imaging and Molecular Biomarkers in Fibrotic ILD
Presenter: Simon Walsh, M.D., Ph.D., Thoracic Radiologist, Qureight Ltd.
Date and Time:
Location: Room 2002/2004 (West Building, Level 2), Moscone Center
Title: WHISTLE-PF: Study Design of A Phase 2b, Multi-center, Randomized, Double-blind, Controlled Trial of ENV-101 (Taladegib) In Patients With Idiopathic Pulmonary Fibrosis
Abstract Session: A74 – Fibrotic Lung Disease Revisited
Presenter: Toby M. Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles
Date and Time: May 18, 2025, 9:15-4:15 p.m. PT
Location: Area G, Hall F, (North Building, Exhibition Level), Moscone Center
For more information about Endeavor BioMedicines and the company's activities at ATS 2025, visit https://endeavorbiomedicines.com/ats.
About Idiopathic Pulmonary Fibrosis
IPF is a chronic, progressive lung disease that affects more than 150,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only three to five years after diagnosis.
About ENV-101
Endeavor BioMedicines' investigational medicine ENV-101 is a Hedgehog signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hedgehog pathway, ENV-101 stops the abnormal accumulation of the myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in pulmonary fibrosis, improving lung volume and function.
About Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). The company's second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) in development for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Forbes
a day ago
- Forbes
How Campus Counseling Centers Can Increase Capacity With Little Money
Broken piggy bank getty Some might believe that increasing the capacity of campus counseling centers to better serve students requires a large financial investment. This perception might seem daunting, especially in light of a 2025 report by Inside Higher Ed describing significant budget cuts at multiple colleges. However, below are five possible ways to increase the capacity of campus counseling centers with little money. A 2022 report by the American Medical Association defined scope of practice as the range of activities that health professionals are authorized, trained and prepared to perform. Health professionals develop a scope of care statement to inform the public about the services they provide. This makes it efficient for when the public is searching for a provider and prevents providers from absorbing into their practice clients with concerns beyond the scope of care. It might be tempting to believe that campus counseling centers should have an unlimited scope of care, and many centers don't provide a concise scope of care statement. However, this goes against best practices. Scope of care statements which summarize the services and limitations of counseling centers are needed. In addition, all staff counselors need to operate under the stated scope of care. When different staff counselors provide different scopes of care to different students, this reduces capacity because stakeholders might expect services that cannot be regularly provided. A indicated by a 2023 report from the Center of Collegiate Mental Health, counseling centers gave 56% of all appointments to 20% of clients. Many of these clients were likely those with high clinical needs who were absorb into their counseling centers' normal operations. As discussed in a 2024 report on using an absorption model to treat students with high needs is often ineffective. It's likely more effective to arrange specialized services for these students, and there are several ways to do this. As discussed in the report on some centers have partnered with treatment centers to bring high level services onto campus. Others might develop memorandums of understanding with off-campus providers to facilitate referrals. Regardless, counseling centers should avoid an absorption model unless they have high capacity and decide to intentionally utilize this model. It's important to note that third-party telehealth vendors may or may not be able to treat students with high clinical needs. Some schools might financially invest into a third-party vendor thinking that more online counselors will automatically increase capacity (and without thinking about scope of care). However, if the counseling center is spending the majority of sessions on high needs students, then a more effective, and often less expensive approach, might be to arrange specialized services for this group of students. A discussed in a 2022 report by Inside Higher Ed, many current counseling center's clients have previously received services from the center. It's not surprising that, without after-care services, many students with episodic symptoms will return to the center and need additional services. There are several ways to provide after-care services. Some centers might provide individualized self-management plans upon termination of counseling. As discussed in the report by Inside Higher Ed, other centers might expand the principles within the field of substance use disorders and promote a mindset of recovery and peer support for those who've completed counseling. The report by Inside Higher Ed also discussed how many staff counselors experience high levels of burnout. Because counselors with high levels of burnout might be less efficient, counseling centers should address sources of high burnout. For some counselors, serving on crisis/on-call rotations is a high source of burnout; however, other staff members might enjoy this work more than carrying a caseload. Thus, realigning staff duties to accommodate these preferences might be helpful. Other options include flex-scheduling, pre-determined caseload sizes, reducing outside committee assignments, and regular team building and self-care activities. Many counseling centers have a robust mental health outreach program, but sometimes these programs are similar to those provided by a campus health promotion office. For large campuses, redundant programing is often needed, and there may be times in which saturating a campus with an outreach initiative is warranted. However, if a counseling center is struggling with capacity, and the campus has an active health promotion office, then it might be helpful for the health promotion office to take the lead in conducting outreaches. It's possible that other campus partners can also meet certain sub-clinical needs better than the counseling center. For example, a student success office might be better equipped to address concerns related to procrastination and time management. Likewise, a student activities office might be better equipped to address homesickness. Few, if any, campus partners can provide the clinical services that the counseling center provides. Thus, avoiding redundant services is often a key to increasing capacity.
